AMSTERDAM — For patients with diffuse cutaneous systemic sclerosis, an autoimmune disease for which there are few treatment options, lenabasum (JBT-101, Corbus Pharmaceuticals) shows potential, new ...

BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune ...

Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

Systemic sclerosis (SSc), also referred to as scleroderma, is a rare autoimmune disease associated with vasculopathy, inflammation, and fibrosis of the skin and/or internal organs. Interstitial lung ...

Following the 2017 American College of Rheumatology (ACR) Annual Meeting—held in San Diego, California, November 3-8—Medscape spoke with Hospital for Special Surgery rheumatologists Dr Robert F.

Please provide your email address to receive an email when new articles are posted on . Patients showed no difference in skin fibrosis whether they were given low-dose oral glucocorticoids or not. One ...

Please provide your email address to receive an email when new articles are posted on . Although lenabasum failed to meet its efficacy endpoint in a trial of patients with diffuse cutaneous systemic ...

Patients who underwent autologous stem cell transplantation (ASCT) for diffuse cutaneous systemic sclerosis (dcSSc), also known as scleroderma, did no better than others receiving conventional ...

Scleroderma, or systemic sclerosis refers to a disorder in which the skin and connective tissues of the body start to thicken and harden because of the overproduction of a protein called collagen.

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...